Belantamab mafodotin – July 2026

  • Brand names:
    • Blenrep®
  • Pharmaceutical Company:
    • GLAXOSMITHKLINE AUSTRALIA PTY LTD
  • Condition/Indication: Relapsed and/or refractory multiple myeloma (MM)
  • Meeting Date: July 2026
Public Summary Documents
Last updated
13 November 2026